New York
Prescription drug spending and prescribing in New York, from Medicare Part D and Medicaid, with the life-science companies raising money there and state attorney general health-care antitrust cases. Compare every state.
In 2024, Medicare Part D plans paid $22.9B for prescriptions written in New York, the 2nd most of 52 states and territories, and 2.1% of its claims were opioids against 3.5% nationally.
- Medicare Part D, 2024: $22.9B
- Medicaid drugs, 2025: $12.7B
- Opioid share of claims: 2.1%
- Life-science raises, 2 years: $3.0B
How It Prescribes
Medicare Part D, 2024, by the prescriber's state| Share of Part D claims | New York | United States | Difference |
|---|---|---|---|
| Opioids | 2.1% | 3.5% | -42% |
| Antibiotics | 4.2% | 4.4% | -6% |
| Antipsychotics | 1.9% | 1.7% | +11% |
Most Distinctive Drugs
Prescribed most out of line with the rest of the country: the drug's share of New York's claims against its share nationally| Drug | Against national rate | Claims |
|---|---|---|
| Ammonium Lactate | 4.8× | 392,373 |
| Alcohol Antiseptic Pads | 4.2× | 482,585 |
| Icosapent Ethyl | 3.7× | 491,503 |
| Ciclopirox Olamine | 3.4× | 112,467 |
| Lifitegrast | 2.9× | 88,675 |
| Clotrimazole | 2.8× | 195,397 |
| Repaglinide | 2.8× | 65,698 |
| Bromfenac Sodium | 2.5× | 42,916 |
| Sitagliptin Phos/Metformin Hcl | 2.5× | 184,704 |
| Collagenase Clostridium Hist. | 2.5× | 43,819 |
Biggest Medicaid Drugs
What New York's Medicaid program paid pharmacies, before rebates; see every drugLife-Science Fundraising
154 Form D raises by companies based in New York in the last two years; the 10 largest. See all raises- Immunovant, Inc.$450M · Pharma · Jan 21, 2025
- Sharps Technology Inc.$411M · Other health care · Oct 31, 2025
- Precision Neuroscience Corp$250M · Other health care · Sep 28, 2026
- Metsera, Inc.$215M · Biotech · Nov 20, 2024
- Rightway Healthcare, Inc.$155M · Other health care · Sep 8, 2026
- VantAI Holdings, Inc.$91M · Other health care · Jan 21, 2026
- ByHeart, Inc.$72M · Other health care · Mar 27, 2025
- Gilgamesh Pharma Inc.$60M · Pharma · Mar 24, 2026
- APPLIED DNA SCIENCES INC$58M · Biotech · Oct 15, 2025
- Diana Health, Inc.$55M · Other health care · Sep 8, 2025
State Attorney General Health-Care Cases
Antitrust cases New York joined, newest first; see every case- Plaintiff States and FTC v. CVET TOPCO, L.P. et al.2026 · Pending
- United States and Plaintiff States v. UnitedHealth et al. (D. Md. 1:24-cv-03267-JKB)2025 · Final judgment
- Connecticut, et al. v. Sandoz, et al., Case No. 20-cv-3539 (E.D. Pa. June 10, 2020), MDL 2724 (E.D. Pa.)2020 · Pending
- FTC et al. v. Vyera Pharmaceuticals, No. 1:20-cv-00706 (S.D.N.Y. Apr. 19, 2020)2020 · Final judgment
- Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al., No. 2:19-cv-02407, (E.D. Pa. filed in MDL 05/30/2019)2019 · Pending
- In the Matter of Investigation of Emergent BioSolutions, Inc.. Assurance No. 19-156 Dec. 31, 2019)2019 · Assurance of discontinuance
- FTC and Plaintiff States v. Mallilnckrodt Ard Inc. (formerly Questcor), No. 1:17-cv-00120 (D.D.C. Jan. 18, 2017)2017 · Settled
- State of Wisconsin et al. v. Indivior, No. 16-5073 (E.D. Pa. Sept. 22,2016)2016 · Pending
- Connecticut et al. v. Teva Pharmaceuticals et al. Civ. Action No. (D.Conn. Dec. 15, 2016)2016 · Pending
- New York et al. v. Cephalon, No. 2:16-cv-04234 (E.D. Pa. Aug. 4, 2016)2016 · Settled
Other States
Alabama · Alaska · Arizona · Arkansas · California · Colorado · Connecticut · Delaware · District of Columbia · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kansas · Kentucky · Louisiana · Maine · Maryland · Massachusetts · Michigan · Minnesota · Mississippi · Missouri · Montana · Nebraska · Nevada · New Hampshire · New Jersey · New Mexico · North Carolina · North Dakota · Ohio · Oklahoma · Oregon · Pennsylvania · Puerto Rico · Rhode Island · South Carolina · South Dakota · Tennessee · Texas · Utah · Vermont · Virginia · Washington · West Virginia · Wisconsin · Wyoming
Part D is by the prescriber's state, Medicaid by the paying state program, and Form D by the issuer's stated address. Amounts are before manufacturer rebates. Refreshed weekly. CMS Medicare Part D Prescribers by Geography; CMS State Drug Utilization Data; SEC Form D; NAAG